Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Applications of synthetic biology in medical and pharmaceutical fields. | Signal Transduct Target Ther | 2023 | 37169742 | PubTator, text mining | PubMed |
| A Winning New Combination? Toward Clinical Application in Oncology. | Cancer Control | 2023 | 37166227 | PubTator, text mining | PubMed |
| Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. | Exp Hematol Oncol | 2023 | 37158921 | PubTator, text mining | PubMed |
| CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated. | Oncol Lett | 2023 | 37153038 | PubTator, text mining | PubMed |
| Induction of endoplasmic reticulum stress is associated with the anti-tumor activity of monepantel across cancer types. | Cancer Med | 2023 | 37148543 | PubTator, text mining | PubMed |
| New cell sources for CAR-based immunotherapy. | Biomark Res | 2023 | 37147740 | PubTator, text mining | PubMed |
| Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. | Ann Rheum Dis | 2023 | 37147112 | PubTator, text mining | PubMed |
| Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time? | Front Immunol | 2023 | 37143664 | PubTator, text mining | PubMed |
| In vivo CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address. | Front Med (Lausanne) | 2023 | 37138754 | PubTator, text mining | PubMed |
| An observational human study investigating the effect of anabolic androgenic steroid use on the transcriptome of skeletal muscle and whole blood using RNA-Seq. | BMC Med Genomics | 2023 | 37138349 | PubTator, text mining | PubMed |
| γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. | Sci Adv | 2023 | 37134157 | PubTator, text mining | PubMed |
| The Notch signaling pathway: a potential target for cancer immunotherapy. | J Hematol Oncol | 2023 | 37131214 | PubTator, text mining | PubMed |
| An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. | Hemasphere | 2023 | 37125259 | PubTator, text mining | PubMed |
| Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells. | Mol Ther Nucleic Acids | 2023 | 37125150 | PubTator, text mining | PubMed |
| Immunotherapy in glioblastoma treatment: Current state and future prospects. | World J Clin Oncol | 2023 | 37124134 | PubTator, text mining | PubMed |
| Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells. | Front Immunol | 2023 | 37122703 | PubTator, text mining | PubMed |
| Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. | Front Immunol | 2023 | 37122702 | PubTator, text mining | PubMed |
| Multi-targeted immunotherapeutics to treat B cell malignancies. | J Control Release | 2023 | 37121515 | PubTator, text mining | PubMed |
| Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. | Cancer Res | 2023 | 37115855 | PubTator, text mining | PubMed |
| Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. | Molecules | 2023 | 37110590 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=32